These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 8326983)

  • 1. Treatment of acute myocardial infarction.
    Hughes-Davies TH
    N Engl J Med; 1993 Aug; 329(6):431; author reply 432-3. PubMed ID: 8326983
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of acute myocardial infarction in Switzerland: is emergency PTCA more costly than thrombolysis?].
    Hagmann A; Amann W; Urban P; Pfisterer M
    Schweiz Med Wochenschr; 1999 Oct; 129(39):1389-96. PubMed ID: 10542996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost of an open infarct-related artery: comparison of treatment modalities in the reperfusion era.
    Aguirre FV
    Mayo Clin Proc; 1994 Jan; 69(1):87-9. PubMed ID: 8271856
    [No Abstract]   [Full Text] [Related]  

  • 4. Myocardial infarction, thrombolytic therapy, and economics.
    Shander D
    Clin Cardiol; 1993 Nov; 16(11):845. PubMed ID: 8269667
    [No Abstract]   [Full Text] [Related]  

  • 5. rTPA: why do we waste these hundreds of millions of dollars?
    Goldstein S
    JAMA; 1991 Jul; 266(3):364. PubMed ID: 1905362
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost effectiveness of tissue plasminogen activator.
    Lee TH
    N Engl J Med; 1995 May; 332(21):1443-4. PubMed ID: 7723804
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
    N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hospital cost of acute myocardial infarction in the thrombolytic era.
    Mahon NG; Rahallaigh PO; O'Sullivan JB; Codd MB; McCann HA; Sugrue DD
    Ir Med J; 2000 Jun; 93(4):122. PubMed ID: 11037575
    [No Abstract]   [Full Text] [Related]  

  • 9. [Are the publicized advantages of thrombolytic treatment of myocardial infarct with recombinant t-PA (ACTILYSE) in comparison with streptokinase so decisive, that despite the high cost a general use of ACTILYSE is justified?].
    Gulba DC
    Internist (Berl); 1992 May; 33(5):364-5. PubMed ID: 1612871
    [No Abstract]   [Full Text] [Related]  

  • 10. Thrombolytic therapy for acute myocardial infarction: GUSTO criticized.
    Chelluri L; Sirio CA; Angus DC
    N Engl J Med; 1994 Feb; 330(7):505; author reply 505-6. PubMed ID: 8289862
    [No Abstract]   [Full Text] [Related]  

  • 11. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cost-effectiveness of primary PTCA and thrombolysis in the treatment of acute myocardial infarction].
    Sagmeister M; Amann FW; Follath F
    Schweiz Med Wochenschr; 2000 Aug; 130(33):1146-51. PubMed ID: 11005104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost, uncertainty, and doctors' decisions. The case of thrombolytic therapy.
    Lessler DS; Avins AL
    Arch Intern Med; 1992 Aug; 152(8):1665-72. PubMed ID: 1497400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary PTCA versus thrombolysis with tPA in acute myocardial infarction: a formal cost-effectiveness analysis.
    Müllner M; Paulis M; Nikfardjam M; Domanovits H; Huber K
    Wien Klin Wochenschr; 1999 Jan; 111(1):37-41. PubMed ID: 10067269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hospitalization costs of primary stenting versus thrombolysis in acute myocardial infarction: cost analysis of the Canadian STAT Study.
    Le May MR; Davies RF; Labinaz M; Sherrard H; Marquis JF; Laramée LA; O'Brien ER; Williams WL; Beanlands RS; Nichol G; Higginson LA
    Circulation; 2003 Nov; 108(21):2624-30. PubMed ID: 14597591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective].
    Lorenzoni R; Fattore G; Gensini G
    G Ital Cardiol; 1997 Jul; 27(7):721-6. PubMed ID: 9303862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergent decision-making: defining the patient perspective.
    Knudtson ML
    Can J Cardiol; 2005 Apr; 21(5):433-4. PubMed ID: 15861261
    [No Abstract]   [Full Text] [Related]  

  • 18. Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs.
    Tsui W; Pierre K; Massel D
    Can J Cardiol; 2005 Apr; 21(5):423-31. PubMed ID: 15861260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thrombolytic therapy].
    de Gaetano G; Donati MB; Gensini GF; Restagno C
    Recenti Prog Med; 1993 Sep; 84(9):581-5. PubMed ID: 8210621
    [No Abstract]   [Full Text] [Related]  

  • 20. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.